A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 4, 2008, Pages 631-646

  Chow, Laura Q M ^a   Eckhardt, S Gail ^a   O'Bryant, Cindy L ^a   Schultz, Mary Kay ^a   Morrow, Mark ^a   Grolnic, Stacy ^a   Basche, Michele ^a   Gore, Lia ^a,b,c  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Cisplatin; Farnesyltransferase; Gemcitabine; Lonafarnib; Pharmacokinetics; Phase I; SCH66336

Indexed keywords

CAPECITABINE; CARBOPLATIN; CELECOXIB; CHAPERONE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; LONAFARNIB; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN HDJ2; TAMOXIFEN; TRASTUZUMAB;

ABDOMINAL DISTENSION; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BILE DUCT CARCINOMA; BLOATING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE METASTASIS; BREAST CANCER; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSPEPSIA; ENZYME ACTIVITY; ENZYME INHIBITION; FARNESYLATION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; HYPOKALEMIA; HYPOTENSION; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALAISE; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN PROCESSING; RASH; SARCOMA; SENSORY NEUROPATHY; SOLID TUMOR; SYNCOPE; THROMBOCYTOPENIA; TINNITUS; TREATMENT RESPONSE; VISUAL DISORDER; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FARNESYLTRANSTRANSFERASE; FATIGUE; FEMALE; HSP40 HEAT-SHOCK PROTEINS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NAUSEA; PIPERIDINES; PYRIDINES; TREATMENT OUTCOME; VOMITING;

EID: 47549092775     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0646-x     Document Type: Article

References (46)

1. V Adamo C Magno G Spitaleri C Garipoli C Maisano E Alafaci B Adamo R Rossello G Scandurra A Scimone 2005 Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen Oncology 69 391 398
2. AA Adjei GA Croghan C Erlichman RS Marks JM Reid JA Sloan HC Pitot SR Alberts RM Goldberg LJ Hanson LM Bruzek P Atherton A Thibault PA Palmer SH Kaufmann 2003 A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer Clin Cancer Res 9 2520 2526
3. AA Adjei JN Davis LM Bruzek C Erlichman SH Kaufmann 2001 Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines Clin Cancer Res 7 1438 1445
4. AA Adjei JN Davis C Erlichman PA Svingen SH Kaufmann 2000 Comparison of potential markers of farnesyltransferase inhibition Clin Cancer Res 6 2318 2325
5. AA Adjei C Erlichman JN Davis DL Cutler JA Sloan RS Marks LJ Hanson PA Svingen P Atherton WR Bishop P Kirschmeier SH Kaufmann 2000 A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity Cancer Res 60 1871 1877
6. HR Ashar L Armstrong LJ James DM Carr K Gray A Taveras RJ Doll WR Bishop PT Kirschmeier 2000 Biological effects and mechanism of action of farnesyl transferase inhibitors Chem Res Toxicol 13 949 952
7. A Awada FA Eskens M Piccart DL Cutler A van der Gaast H Bleiberg J Wanders MN Faber P Statkevich P Fumoleau J Verweij 2002 Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours Eur J Cancer 38 2272 2278
8. MM Bradford 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal Biochem 72 248 254
9. F Caponigro 2002 Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002 Anticancer Drugs 13 891 897
10. G Colucci F Giuliani V Gebbia M Biglietto P Rabitti G Uomo S Cigolari A Testa E Maiello M Lopez 2002 Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale Cancer 94 902 910
11. L Crino 2002 Combined platinum containing treatment in NSCLC Lung Cancer 38 Suppl 3 S51 S52
12. L Crino C Calandri 2002 Gemzar platinum combinations: phase III trials in non-small cell lung cancer Lung Cancer 38 Suppl 2 S9 S12
13. FA Eskens A Awada DL Cutler MJ de Jonge GP Luyten MN Faber P Statkevich A Sparreboom J Verweij AR Hanauske M Piccart 2001 Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors J Clin Oncol 19 1167 1175
14. H Fuentes G Calderillo F Alexander M Ramirez E Avila L Perez G Aguirre LF Onate-Ocana D Gallardo J Otero 2006 Phase II study of gemcitabine plus cisplatin in metastatic breast cancer Anticancer Drugs 17 565 7570
15. D Gallardo G Calderillo A Serrano F Alexander G Rodriguez L Perez J de la Garza L Orate-Ocana J Otero 2006 A phase II study of gemcitabine plus cisplatin in previously untreated advanced ovarian cancer Anticancer Res 26 3137 3141
16. JB Gibbs SL Graham GD Hartman KS Koblan NE Kohl CA Omer A Oliff 1997 Farnesyltransferase inhibitors versus Ras inhibitors Curr Opin Chem Biol 1 197 203
17. L Gore SN Holden RB Cohen M Morrow AS Pierson CL O'Bryant M Persky D Gustafson C Mikule S Zhang PA Palmer SG Eckhardt 2006 A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors Ann Oncol 17 1709 1717
18. WZ Gu I Joseph YC Wang D Frost GM Sullivan L Wang NH Lin J Cohen VS Stoll CG Jakob SW Muchmore JE Harlan T Holzman KA Walten US Ladror MG Anderson P Kroeger LE Rodriguez KP Jarvis D Ferguson K Marsh S Ng SH Rosenberg HL Sham H Zhang 2005 A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies Anticancer Drugs 16 1059 1069
19. SK Gupta S John R Naik R Arora B Selvamani J Fuloria N Ganesh BS Awasthy 2005 A multicenter phase II study of gemcitabine, paclitaxel, and cisplatin in chemonaive advanced ovarian cancer Gynecol Oncol 98 134 140
20. P Haluska GK Dy AA Adjei 2002 Farnesyl transferase inhibitors as anticancer agents Eur J Cancer 38 1685 1700
21. J Head SR Johnston 2004 New targets for therapy in breast cancer: farnesyltransferase inhibitors Breast Cancer Res 6 262 268
22. V Heinemann 2003 Role of gemcitabine in the treatment of advanced and metastatic breast cancer Oncology 64 191 206
23. Izbicka E, Lawrence R, Davidson K et. al (1999) Activity of a farnesyl transferase inhibitor (SCH 66336) against a broad range of tumors taken directly from patients. (abstr 3454). Proc Am assoc Cancer Res
24. SR Johnston T Hickish P Ellis S Houston L Kelland M Dowsett J Salter B Michiels JJ Perez-Ruixo P Palmer A Howes 2003 Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer J Clin Oncol 21 2492 2496
25. T Le Chevalier G Scagliotti R Natale S Danson R Rosell R Stahel P Thomas RM Rudd J Vansteenkiste N Thatcher C Manegold JL Pujol N van Zandwijk C Gridelli JP van Meerbeeck L Crino A Brown P Fitzgerald M Aristides JH Schiller 2005 Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes Lung Cancer 47 69 80
26. M Liu MS Bryant J Chen S Lee B Yaremko P Lipari M Malkowski E Ferrari L Nielsen N Prioli J Dell D Sinha J Syed WA Korfmacher AA Nomeir CC Lin L Wang AG Taveras RJ Doll FG Njoroge AK Mallams S Remiszewski JJ Catino VM Girijavallabhan WR Bishop 1998 Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice Cancer Res 58 4947 4956
27. M Loprevite RE Favoni A De Cupis T Scolaro C Semino P Mazzanti A Ardizzoni 2004 In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell lines Oncol Rep 11 407 414
28. TZ Mohran 2004 Gemcitabine and cisplatin combination chemotherapy as a first-line treatment in patients with metastatic breast cancer J Egypt Natl Canc Inst 16 8 14
29. RA Nagourney CA Brewer S Radecki WA Kidder BL Sommers SS Evans DR Minor PJ DiSaia 2003 Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients Gynecol Oncol 88 35 39
30. RK Ngan HH Yiu WH Lau S Yau FY Cheung TM Chan CH Kwok CY Chiu SK Au W Foo CK Law KC Tse 2002 Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study Ann Oncol 13 1252 1258
31. GJ Peters VW van Ruiz Haperen AM Bergman G Veerman E Smitskamp-Wilms CJ van Moorsel CM Kuiper BJ Braakhuis 1996 Preclinical combination therapy with gemcitabine and mechanisms of resistance Semin Oncol 23 16 24
32. T Petit E Izbicka RA Lawrence WR Bishop S Weitman DD Von Hoff 1999 Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units Ann Oncol 10 449 453
33. Predergast J (1999) Targeting farnesyltransferase: is ras relevant? In: Oncology ASoC (ed). ASCO educational book, pp. 22-28
34. NE Ready A Lipton Y Zhu P Statkevich E Frank D Curtis RM Bukowski 2007 Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors Clin Cancer Res 13 576 583
35. JE Rosenberg PR Carroll EJ Small 2005 Update on chemotherapy for advanced bladder cancer J Urol 174 14 20
36. EK Rowinsky JJ Windle DD Von Hoff 1999 Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development J Clin Oncol 17 3631 3652
37. A Sandler DS Ettinger 1999 Gemcitabine: single-agent and combination therapy in non-small cell lung cancer Oncologist 4 241 251
38. GV Scagliotti F De Marinis M Rinaldi L Crino C Gridelli S Ricci E Matano C Boni M Marangolo G Failla G Altavilla V Adamo A Ceribelli M Clerici F Di Costanzo L Frontini M Tonato 2002 Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer J Clin Oncol 20 4285 4291
39. Schering-Plough (2003.) Lornafarnib (SCH 66336) investigator's brochure. Schering-Plough Research Institute, December 2003 Report
40. JH Seo SC Oh CW Choi BS Kim SW Shin YH Kim JS Kim AR Kim JB Lee BH Koo 2007 Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer Cancer Chemother Pharmacol 59 269 274
41. FA Shepherd R Abratt L Crino M Green A Sandler W Steward J Iglesias G Anglin 2000 The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer Lung Cancer 30 117 125
42. KS Smalley TG Eisen 2003 Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells Int J Cancer 105 165 75
43. J Sun M Blaskovich D Knowles 1999 Anti-tumor efficacy of a novel class of non-thiol containing peptidomemimetic inhibitors of farnesyltransferase and geranylgeranyl transferase I: combination therapy with the cytotoxic agents cisplatin, taxol and gemcitabine Cancer Res 59 4919 4926
44. AG Taveras P Kirschmeier CM Baum 2003 Sch-66336 (sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations Curr Top Med Chem 3 1103 1114
45. C Theodore L Geoffrois JB Vermorken F Caponigro W Fiedler P Chollet A Ravaud GJ Peters C de Balincourt D Lacombe P Fumoleau 2005 Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor and gemcitabine combination in salvage treatment of advanced urothelial tract cancers Eur J Cancer 41 1150 1157
46. E Wang CN Casciano RP Clement WW Johnson 2001 The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein Cancer Res 61 7525 7529